Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Tiotropium/Salmeterol QDDrug: Placebo
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 220
- Registration Number
- NCT00662740
- Locations
- 🇺🇸
1184.14.01006 Boehringer Ingelheim Investigational Site, Winter Park, Florida, United States
🇺🇸1184.14.01015 Boehringer Ingelheim Investigational Site, South Bend, Indiana, United States
🇳🇱1184.14.31001 Boehringer Ingelheim Investigational Site, Veldhoven, Netherlands
Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Tiotropium/Salmeterol (T+S_PE)
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 147
- Registration Number
- NCT00662792
- Locations
- 🇩🇪
1184.13.1312 Boehringer Ingelheim Investigational Site, Hamburg, Germany
🇩🇪1184.13.1305 Boehringer Ingelheim Investigational Site, Mainz, Germany
🇩🇪1184.13.1301 Boehringer Ingelheim Investigational Site, Mannheim, Germany
Telmisartan+HCTZ (Hydrochlorothiazide), Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6901
- Registration Number
- NCT00659607
- Locations
- 🇰🇷
Boehringer Ingelheim Investigational Site 14, Seoul, Korea, Republic of
🇰🇷Boehringer Ingelheim Investigational Site 15, Seoul, Korea, Republic of
🇰🇷Boehringer Ingelheim Investigational Site 12, Seoul, Korea, Republic of
J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 21471
- Registration Number
- NCT00659581
Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2055
- Registration Number
- NCT00657150
- Locations
- 🇺🇸
1160.64.01003 Boehringer Ingelheim Investigational Site, Missoula, Montana, United States
🇺🇸1160.64.01002 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇨🇦1160.64.6011 Boehringer Ingelheim Investigational Site, Oshawa, Ontario, Canada
BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 585
- Registration Number
- NCT00656136
- Locations
- 🇧🇪
1200.23.32004 Boehringer Ingelheim Investigational Site, Edegem, Belgium
🇧🇪1200.23.32005 Boehringer Ingelheim Investigational Site, Liège, Belgium
🇨🇦1200.23.1001 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada
Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 306
- Registration Number
- NCT00654498
- Locations
- 🇨🇳
248.630.06 Boehringer Ingelheim Investigational Site, Beijing, China
🇨🇳248.630.07 Boehringer Ingelheim Investigational Site, Beijing, China
🇨🇳248.630.01 Boehringer Ingelheim Investigational Site, Shanghai, China
Japanese P III vs Voglibose and Placebo
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 561
- Registration Number
- NCT00654381
- Locations
- 🇯🇵
1218.23.33 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan
🇯🇵1218.23.35 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan
🇯🇵1218.23.19 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan
Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment
- Conditions
- Parkinson Disease
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 286
- Registration Number
- NCT00651183
- Locations
- 🇦🇹
Boehringer Ingelheim Investigational Site, Wörgl, Austria
Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: placebo + pioglitazone (30 mg)
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 389
- Registration Number
- NCT00641043
- Locations
- 🇭🇺
1218.15.36002 Boehringer Ingelheim Investigational Site, Szombathely, Hungary
🇪🇸1218.15.34006 Boehringer Ingelheim Investigational Site, Madrid, Spain
🇬🇷1218.15.30006 Boehringer Ingelheim Investigational Site, Thessaloniki, Greece